Citations

Clear

16281 citation(s) found for "Yu, David".

Short-term risk of fracture is increased by deficits in cortical and trabecular bone microarchitecture independent of DXA BMD and FRAX: Bone Microarchitecture International Consortium (BoMIC) prospective cohorts
Sarfati, Marine, Merle, Blandine , Boyd, Steven K. , Whittier, Danielle E. , Hanley, David A. , Szulc, Paweł , Mellström, Dan, Bouxsein, Mary , Boyd, Steven K , Whittier, Danielle E , Hanley, David A , Wong, Andy Kin On , Lespessailles, Eric , Lorentzon, Mattias , Kiel, Douglas P , Hannan, Marian T , Szulc, Pawel , Chapurlat, Roland D , Dufour, Alyssa B , Sornay‐Rendu, Elisabeth , Goltzman, David , Wong, Andy Kin On , Lespessailles, Éric , Khosla, Sundeep , Ferrari, Serge , Biver, Emmanuel , Ohlsson, Claes , Lorentzon, Mattias , Nethander, Maria , Samelson, Elizabeth J , Kiel, Douglas P. , Hannan, Marian T.

Mayo Clinic

Journal of Bone and Mineral Research | September 5, 2024 | Volume: 39 | Issue: 11 | Pages: 1574-1583

10.1093/jbmr/zjae143 | PMID 39236248 Get It

Abstract Identifying individuals at risk for short-term fracture is essential to offer prompt beneficial treatment, especially since many fractures occur in those without osteoporosis by DXA-aBMD. We evaluated whether deficits in bone microarchitecture and density predict short-term fracture risk independent of the clinical predictors, DXA-BMD and FRAX. We combined data from eight cohorts to conduct a prospective study of bone microarchitecture at the distal radius and tibia (by HR-pQCT) and 2-year incidence of fracture (non-traumatic and traumatic) in 7327 individuals (4824 women, 2503 men, mean 69 ± 9 years). We estimated sex-specific hazard ratios (HR) for associations between bone measures and 2-year fracture incidence, adjusted for age, cohort, height, and weight, and then additionally adjusted for FN aBMD or FRAX for major osteoporotic fracture. Only 7% of study participants had FN T-score ≤ −2.5, whereas 53% had T-scores between −1.0 and −2.5 and 37% had T-scores ≥−1.0. Two-year cumulative fracture incidence was 4% (296/7327). Each SD decrease in radius cortical bone measures increased fracture risk by 38%-76% for women and men. After additional adjustment for FN-aBMD, risks remained increased by 28%-61%. Radius trabecular measures were also associated with 2-year fracture risk independently of FN-aBMD in women (HRs range: 1.21 per SD for trabecular separation to 1.55 for total vBMD). Decreased failure load (FL) was associated with increased fracture risk in both women and men (FN-aBMD ranges of adjusted HR = 1.47-2.42). Tibia measurement results were similar to radius results. Findings were also similar when models were adjusted for FRAX. In older adults, FL and HR-pQCT measures of cortical and trabecular bone microarchitecture and density with strong associations to short-term fractures improved fracture prediction beyond aBMD and FRAX. Thus, HR-pQCT may be a useful adjunct to traditional assessment of short-term fracture risk in older adults, including those with T-scores above the osteoporosis range.
Abstract B022: Precision medicine for the fusion protein driven cancer, fibrolamellar carcinoma (FLC): Beyond sequencing
Shirani, Mahsa , Requena, David , Ng, Denise , Molina, Henrik , Rice, Charles M. , Lyons, Barbara A. , Requena, David , Simon, Sanford M. , Lalazar, Gadi , Levin, Solomon , Torbenson, Michael , Singhi, Aatur Dilip , Coffino, Philip

Mayo Clinic

Cancer Research | September 5, 2024 | Volume: 84 | Issue: 17_Supplement | Pages: B022-B022

10.1158/1538-7445.pediatric24-b022 Get It

Abstract Fibrolamellar carcinoma (FLC) is a rare, usually lethal primary liver tumor that affects children, adolescents and young adults. Sequencing of FLC tumors in hepatocytes reveals that in 99% of the patients there is one recurrent genomic alteration: A deletion of 400 kB. This produces DNAJB1::PRKACA, a fusion of the first exon of DNAJB1 with the 2nd – 10th exons of PRKACA, the catalytic subunit of protein kinase A (PKA). PKA exists as a holoenzyme of two catalytic subunits and two regulatory subunits. The regulatory subunit both inhibits the catalytic and localizes it in the cell. Calibrated mass spectrometry shows that in normal liver there is always an excess of regulatory>catalytic subunits, but in the adjacent FLC tumor tissue there is an excess of catalytic>regulatory subunits. Different biochemistry assays and proximity ligation reveal both free catalytic, unbound to regulatory subunits, and an increase of kinase activity in the tumor cells. Much of the increase of catalytic subunit is in the nucleus. Transducing primary human hepatocytes (PHH) with DNAJB1::PRKACA is sufficient to recapitulate the transcriptome of FLC tumors. Transduction of PHH with just the wt PRKACA is also sufficient to recapitulate the transcriptome of FLC tumors. Thus, just increasing the level of kinase is sufficient, there is nothing special about the fusion domain. From our tissue repository we have four patients who have a tumor that looks like FLC but does not have a fusion to the catalytic subunit. The only alteration in these patients is loss of regulatory subunit. The transcriptome of these patient tumors is indistinguishable from that of classic DNAJB1::PRKACA FLC in hepatocytes. Additionally, we have a few dozen patients who have either DNAJB1::PRKACA or another fusion, ATP1B1::PRKACA in the ductal cells of their liver (producing cholangiocarcinomas) or ductal cells of their pancreas (producing IOPN, Intraductal Oncolytic Pancreatic Neoplasms). The transcriptome of these patients clusters with the transcriptome of the FLC patients with DNAJB1::PRKACA in the hepatocytes. A functional precision medicine drug repurposing screen found that the EC50 of the response of freshly resected tumors from patients to a wide panel of drugs is the same as that of FLC patients with DNAJB1::PRKACA in their hepatocytes. Based on sequencing one could conclude that patients with deletion of regulatory subunit in the hepatocytes, or expression of DNAJB1::PRKACA in the hepatocytes, or expression of DNAJB1::PRKACA or ATP1B1::PRKACA in the cholangiocytes or pancreatic ductal cells are at least three distinct diseases. An analysis of the cell biological changes reveals that they all of an increase of the ratio of catalytic:regulatory subunit, they have an increase of catalytic subunit in the nucleus, and these all result in the same changes of transcriptome and the same drug-response profile. Thus, looking beyond sequencing to the cellular changes leads to a different conclusion, that maybe they should be considered the same disease. Citation Format: Sanford Simon, Mahsa Shirani, David Requena, Denise Ng, Gadi Lalazar, Solomon Levin, Michael S. Torbenson, Aatur D. Singhi, Henrik Molina, Charles M. Rice, Philip Coffino, Barbara A. Lyons. Precision medicine for the fusion protein driven cancer, fibrolamellar carcinoma (FLC): Beyond sequencing [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pediatric Cancer Research; 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl):Abstract nr B022.
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Llor, Xavier , Abbass, Mohammad Ali , Chen, Christopher T. , Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Fudman, David , Giardiello, Francis M., Glaser, Kathryn , Gurudu, S, Hall, Michael J. , Issaka, Rachel B. , Kidambi, Trilokesh D. , Lazenby, Audrey J., Maratt, Jennifer K. , Markowitz, Arnold J. , Marsano, Joseph, Olortegui, Kinga Skowron , Peter, Shajan , Porter, Laura , Shafi, Mehnaz, Terdiman, Jonathan P., Vu, Peter , Wood, Elizabeth H., Cassara, Carly J., Gurudu, Surya, Ness, Reid M. , Bishu, Shrinivas , Huang, Lyen C. , Katona, Bryson W , May, Folasade P. , Mayer, Robert J. , Olortegui, Kinga S. , Patel, Swati , Stanich, Peter P. , Weiss, Jennifer M. , Wood, Elizabeth, Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 438-446

10.6004/jnccn.2024.0047 | PMID 39236750 Get It

The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age at which to initiate screening in average-risk individuals and those with increased risk based on personal history of childhood, adolescent, and young adult cancer.
Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium
McCleary, Nadine J. , Merle, James L. , Richardson, Joshua E. , Garcia, Sofia F. , Tesch, Nathan , DiMartino, Lisa , Hassett, Michael J. , Cella, David , Smith, Justin D. , Kroner, Barbara L, Ruddy, Kathryn, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Cahue, September, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Faris, Nicolas, Flores, Anne Marie, Garcia, Martha, Hodgdon, Christine, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearson, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Richardson, Kimberly, Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tramontano, Angela C. , Wong, Sandra , Cella, David , Garcia, Sofia F , Bass, Michael , Cheville, Andrea , Mitchell, Sandra A , Jensen, Roxanne E. , Minteer, Sarah A. , Austin, Jessica D. , Osarogiagbon, Raymond U. , Wong, Sandra L. , Schrag, Deborah , Smith, Ashley Wilder , Kroner, Barbara L, Griffin, Joan M. , Ruddy, Kathryn J. , Ardini, Mary-Anne , Barrett, Fiona, Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Popovic, Jennifer R. , Preiss, Liliana , Reich, James, Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JAMIA Open | September 5, 2024 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/jamiaopen/ooae081 | PMID 39234146 Get It

AbstractObjectivesTo report lessons from integrating the methods and perspectives of clinical informatics (CI) and implementation science (IS) in the context of Improving the Management of symPtoms during and following Cancer Treatment (IMPACT) Consortium pragmatic trials.Materials and MethodsIMPACT informaticists, trialists, and implementation scientists met to identify challenges and solutions by examining robust case examples from 3 Research Centers that are deploying systematic symptom assessment and management interventions via electronic health records (EHRs). Investigators discussed data collection and CI challenges, implementation strategies, and lessons learned.ResultsCI implementation strategies and EHRs systems were utilized to collect and act upon symptoms and impairments in functioning via electronic patient-reported outcomes (ePRO) captured in ambulatory oncology settings. Limited EHR functionality and data collection capabilities constrained the ability to address IS questions. Collecting ePRO data required significant planning and organizational champions adept at navigating ambiguity.DiscussionBringing together CI and IS perspectives offers critical opportunities for monitoring and managing cancer symptoms via ePROs. Discussions between CI and IS researchers identified and addressed gaps between applied informatics implementation and theory-based IS trial and evaluation methods. The use of common terminology may foster shared mental models between CI and IS communities to enhance EHR design to more effectively facilitate ePRO implementation and clinical responses.ConclusionImplementation of ePROs in ambulatory oncology clinics benefits from common understanding of the concepts, lexicon, and incentives between CI implementers and IS researchers to facilitate and measure the results of implementation efforts.
Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?
Gebre, Robel K , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Raghavan, Sheelakumari, Hofrenning, Ekaterina I. , Przybelski, Scott A. , Nguyen, Aivi T. , Lesnick, Timothy G. , Gunter, Jeffrey L. , Vassilaki, Maria , Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald C. , Algeciras-Schimnich, Alicia , Knopman, David S. , Vassilaki, Maria , Jack, Clifford R , Vemuri, Prashanthi , Nguyen, Aivi T , Ramanan, Vijay K , Raghavan, Sheelakumari , Algeciras‐Schimnich, Alicia , Knopman, David S. , Machulda, Mary M. , Vemuri, Prashanthi

Mayo Clinic

Brain Communications | September 5, 2024 | Volume: 6 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcae300 | PMID 39291164 Get It

Abstract There is increasing interest in Alzheimer’s disease related plasma biomarkers due to their accessibility and scalability. We hypothesized that integrating plasma biomarkers with other commonly used and available participant data (MRI, cardiovascular factors, lifestyle, genetics) using machine learning (ML) models can improve individual prediction of cognitive outcomes. Further, our goal was to evaluate the heterogeneity of these predictors across different age strata. This longitudinal study included 1185 participants from the Mayo Clinic Study of Aging who had complete plasma analyte work-up at baseline. We used the Quanterix Simoa immunoassay to measure neurofilament light, Aβ1–42 and Aβ1–40 (used as Aβ42/Aβ40 ratio), glial fibrillary acidic protein, and phosphorylated tau 181 (p-tau181). Participants’ brain health was evaluated through gray and white matter structural MRIs. The study also considered cardiovascular factors (hyperlipidemia, hypertension, stroke, diabetes, chronic kidney disease), lifestyle factors (area deprivation index, body mass index, cognitive and physical activities), and genetic factors (APOE, single nucleotide polymorphisms, and polygenic risk scores). An ML model was developed to predict cognitive outcomes at baseline and decline (slope). Three models were created: a base model with groups of risk factors as predictors, an enhanced model included socio-demographics, and a final enhanced model by incorporating plasma and socio-demographics into the base models. Models were explained for three age strata: younger than 65 years, 65–80 years, and older than 80 years, and further divided based on amyloid positivity status. Regardless of amyloid status the plasma biomarkers showed comparable performance (R² = 0.15) to MRI (R² = 0.18) and cardiovascular measures (R² = 0.10) when predicting cognitive decline. Inclusion of cardiovascular or MRI measures with plasma in the presence of socio-demographic improved cognitive decline prediction (R² = 0.26 and 0.27). For amyloid positive individuals Aβ42/Aβ40, glial fibrillary acidic protein and p-tau181 were the top predictors of cognitive decline while Aβ42/Aβ40 was prominent for amyloid negative participants across all age groups. Socio-demographics explained a large portion of the variance in the amyloid negative individuals while the plasma biomarkers predominantly explained the variance in amyloid positive individuals (21% to 37% from the younger to the older age group). Plasma biomarkers performed similarly to MRI and cardiovascular measures when predicting cognitive outcomes and combining them with either measure resulted in better performance. Top predictors were heterogeneous between cross-sectional and longitudinal cognition models, across age groups, and amyloid status. Multimodal approaches will enhance the usefulness of plasma biomarkers through careful considerations of a study population’s socio-demographics, brain and cardiovascular health.
Evaluating the Impact of Robotic Ileal Pouch-anal Anastomosis
Violante, Tommaso , Novelli, Marco , Perry, William , Mathis, Kellie L. , Dozois, Eric J. , Merchea, Amit , Shawki, Sherief S., Perry, William R., Violante, Tommaso , Perry, William R , Ferrari, Davide , Behm, Kevin T. , Shawki, Sherief , Larson, David W.

Mayo Clinic

Annals of Surgery | September 5, 2024 | Volume: 283 | Issue: 3 | Pages: 513-518

10.1097/sla.0000000000006524 | PMID 39234747 Get It

Objective: To compare robotic-assisted proctectomy with ileal pouch-anal anastomosis (R-IPAA) outcomes and laparoscopic proctectomy with IPAA within a specialized robotic surgery center, using matching techniques to minimize potential confounding factors. Background: Minimally invasive approaches, particularly laparoscopy, have improved outcomes for patients with inflammatory bowel disease and familial adenomatous polyposis undergoing IPAA. Robotic-assisted surgery offers potential technical advantages, but its definitive superiority over laparoscopy in this context remains under debate. Methods: This retrospective, “Strengthening the Reporting of Observational Studies in Epidemiology”–compliant study analyzed 234 consecutive patients undergoing IPAA (117 robotic and 117 laparoscopic). Data encompassed patient demographics, intraoperative details, and postoperative outcomes. We employed various matching techniques to address potential bias. Primary endpoints focused on 30-day complications, readmissions, and reoperations, with secondary endpoints including hospital stay, blood loss, and stoma closure rates. Results: R-IPAA demonstrated a lower conversion rate to open surgery ( P = 0.02), a shorter hospital stay ( P = 0.04), and reduced blood loss ( P = 0.0003) compared with laparoscopic proctectomy with IPAA. While overall 30-day morbidity rates were similar ( P = 0.4), matched analyses suggested a trend towards fewer reoperations and 3-month IPAA-associated complications after diverting loop ileostomy closure in the robotic group. However, these differences did not reach statistical significance. Conclusions: In a high-volume robotic surgery center, R-IPAA reduced the risk of conversion to open surgery while reducing intraoperative blood loss and providing shorter lengths of stay with equivalent perioperative outcomes. Promising trends to reduce 30-day reoperations and surgical complications after diverting loop ileostomy closure were observed after a matching analysis.
Missense and loss‐of‐function variants at GWAS loci in familial Alzheimer's disease
Gunasekaran, Tamil Iniyan , Reyes‐Dumeyer, Dolly , Faber, Kelley , Goate, Alison , Pericak‐Vance, Margaret, Haines, Jonathan L. , Rosenberg, Roger N., Mejía, Diones Rivera , Medrano, Martin , Lantigua, Rafael , Alba, Camille , Mayeux, Richard , Bennett, David A. , Wilson, Robert S. , Bennett, David A. , Goate, Alison M , Boeve, Bradley F. , Cruchaga, Carlos , Pericak‐Vance, Margaret, Tsuang, Debby W. , Sweet, Robert A. , Soni, Rajesh K , Wilson, Robert S., Dalgard, Clifton L. , Foroud, Tatiana , Vardarajan, Badri Narayan

Mayo Clinic

Alzheimer's & Dementia | September 5, 2024 | Volume: 20 | Issue: 11 | Pages: 7580-7594

10.1002/alz.14221 | PMID 39233587 Get It

Abstract BACKGROUND Few rare variants have been identified in genetic loci from genome‐wide association studies (GWAS) of Alzheimer's disease (AD), limiting understanding of mechanisms, risk assessment, and genetic counseling. METHODS Using genome sequencing data from 197 families in the National Institute on Aging Alzheimer's Disease Family Based Study and 214 Caribbean Hispanic families, we searched for rare coding variants within known GWAS loci from the largest published study. RESULTS Eighty‐six rare missense or loss‐of‐function (LoF) variants completely segregated in 17.5% of families, but in 91 (22.1%) families Apolipoprotein E ( APOE)‐ 𝜀4 was the only variant segregating. However, in 60.3% of families, APOE 𝜀4, missense, and LoF variants were not found within the GWAS loci. DISCUSSION Although APOE 𝜀4and several rare variants were found to segregate in both family datasets, many families had no variant accounting for their disease. This suggests that familial AD may be the result of unidentified rare variants. Highlights Rare coding variants from GWAS loci segregate in familial Alzheimer's disease. Missense or loss of function variants were found segregating in nearly 7% of families. APOE‐𝜀4 was the only segregating variant in 29.7% in familial Alzheimer's disease. In Hispanic and non‐Hispanic families, different variants were found in segregating genes. No coding variants were found segregating in many Hispanic and non‐Hispanic families.
Hypofractionated Preoperative Radiation Should Not Yet Be Used as Standard of Care for Extremity and Truncal Soft Tissue Sarcoma
Baldini, Elizabeth H. , Guadagnolo, B. Ashleigh , Salerno, Kilian , Miah, Aisha , Bedi, Meena , Harris, Jeremy P. , Petersen, Ivy A. , Gillham, Charles, Alektiar, Kaled M. , Kirsch, David G. , Petersen, Ivy, Chung, Peter W M , Bishop, Andrew Justin , Kalbasi, Anusha K. , Wiltink, Lisette M. , Haas, Rick L.

Mayo Clinic

Journal of Clinical Oncology | September 4, 2024 | Volume: 42 | Issue: 36 | Pages: 4240-4245

10.1200/jco.24.00238 | PMID 39231372 Get It

Hypofractionated radiation therapy regimens should not be used as standard of care for localized soft tissue sarcoma
A Call to Start Implementing the Results of High-Quality Randomized Trials in Daily Orthopaedic Practice
Ring, David , Crijns, Tom Joris

Mayo Clinic

Journal of Bone and Joint Surgery | September 4, 2024 | Volume: 106 | Issue: 17 | Pages: e38

10.2106/jbjs.24.00491 | PMID 39230566 Get It

Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary
Kasi, Pashtoon Murtaza , Ma, Li , Hart, Lowell L., Wong, Jenna , Spigel, David R. , Schnabel, Catherine A. , Reeves, James A. , Hálfdánarson, Þorvarður R. , Treuner, Kai , Greco, Frank A. , Fuentes, Harry E , Kasi, Pashtoon Murtaza , Spigel, David R , Halfdanarson, Thorvardur R , Treuner, Kai , Greco, F Anthony , Fuentes, Harry E , Wong, Jenna

Mayo Clinic

JCO Precision Oncology | September 4, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00191 | PMID 39231374 Get It

PURPOSE Cancer of unknown primary (CUP) is a syndrome comprising metastatic cancers without a clinically identified primary site. Although patients with CUP have an unfavorable prognosis, treatment with site-specific therapies guided by clinical features, standard pathology, and molecular assays can improve overall survival. The 92-gene assay (CancerTYPE ID) is a gene expression–based classifier that helps identify the tissue of origin for metastatic cancers with unknown or uncertain diagnoses. This study reports the frequency of selected molecular aberrations of oncogenes, including KRAS, IDH1/2, BRCA1/2, and BRAF, in patients with CUP in the MOSAIC database to highlight potential treatment options. METHODS MOSAIC is a database of patients with CUP submitted for CancerTYPE ID testing and NeoTYPE biomarker testing. Tumor biopsy samples were analyzed by CancerTYPE ID for tumor type identification and further tested for molecular aberrations of oncogenes, including KRAS, IDH1/2, BRCA1/2, and BRAF. RESULTS CancerTYPE ID identified a specific tumor type in 92.5% (2,929 of 3,168) of CUP cases in the MOSAIC database. The most commonly identified histological type was adenocarcinoma (75.4%), with pancreaticobiliary being the most common molecularly diagnosed cancer (24.9%). Aberrations in KRAS, IDH1/2, BRCA, and BRAF genes were identified in 18.8% (n = 597) of biopsies. A cancer-specific US Food and Drug Administration (FDA)–approved or investigational targeted therapy was potentially available for 24.6% (n = 147) of these patients. CONCLUSION This retrospective analysis supports incorporating CancerTYPE ID into the evaluation for patients with CUP to help determine the tissue of origin and identify actionable genetic alterations. This approach may allow more patients with CUP to benefit from site-specific FDA-approved targeted therapies or enrollment into clinical trials.